NRG-GU009 / PREDICT-RT — Genomic-risk-adapted radiotherapy and hormonal therapy in high-risk prostate cancer

Phase 3 · Prostate Cancer

Population

High-risk localized prostate adenocarcinoma.

Primary Endpoint

Metastasis-free survival

Rationale

High-risk prostate cancer is treated uniformly, over-treating some patients and under-treating others. PREDICT-RT uses a genomic classifier to personalize the intensity of radiation and hormonal therapy.

What It Could Change

Could make a genomic risk score routine for tailoring the intensity of prostate radiotherapy.